verve therapeutics eli lilly - Search News

News

Eli Lilly Buys Verve Therapeutics

Beyond Obesity: Eli Lilly’s Genetic Medicine Bet On Verve Therapeutics

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment portfolio.

The Wall Street Journal on MSN · 1d

Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion

Eli Lilly agreed to acquire Verve Therapeutics for about $1 billion upfront, adding a potential treatment for cardiovascular disease to its portfolio. Under the agreement, the pharmaceutical company will buy all of the gene-editing startup’s shares outstanding for $10.

Barron's on MSN · 1d

Eli Lilly’s $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring. What to Know.

Lilly confirmed it would buy a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease.

6h

Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst

Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate.

1don MSN

This one-and-done heart-disease treatment just got a $1.3 billion endorsement from Eli Lilly

Eli Lilly & Co. aims to offer a one-and-done heart-disease medicine by paying up to $1.3 billion for Verve Therapeutics Inc., ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results